Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and ...

The Medicines and Healthcare products Regulatory Agency has authorised Jascayd (nerandomilast) for adults with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis, marking the first new ...

Pulmonary fibrosis—also known in technical terms as idiopathic pulmonary fibrosis (IPF)—is a rare but life-threatening disease. It causes scarring of the connective tissue between the functional ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

IPF is a chronic lung disease with fibrous tissue formation, leading to respiratory decline and poor prognosis, affecting mainly older adults. Diagnosis is challenging due to its exclusionary nature, ...

Idiopathic pulmonary fibrosis stands as one of medicine’s most challenging respiratory conditions, gradually transforming healthy lung tissue into stiff, scarred material that severely compromises ...

Researchers have validated a genetic scoring tool that may help physicians diagnose idiopathic pulmonary fibrosis and ...

Researchers have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.

Princess Mette-Marit of Norway has undergone a lung transplant to treat a progressive disease. What to know.